Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law: 16 (Munich Studies on Innovation and Competition, 16) - Image 1

£90.25

Springer Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law: 16 (Munich Studies on Innovation and Competition, 16)

Name: Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law: 16 (Munich Studies on Innovation and Competition, 16)
Brand: Springer
Price: 90.25 GBP
Availability: InStock

International

Price History & Forecast

Last 10 days • 10 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 10 days • 1 price levels

Days at Price

Price Analysis

Most common price: £90 (10 days, 100.0%)

Price range: £90 - £90

Price levels: 1 different prices over 10 days

Description

Product Description This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors’ control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised. From the Back Cover This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors’ control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised. About the Author Daria Kim is senior research fellow at the Max Planck Institute for Competition and Innovation (Munich), where she works on the topics related to the regulation of the data economy and life sciences. Prior to joining Max Planck Institute, she worked as a research associate at the Chinese University of Hong Kong. She holds MA (Indiana University of Pennsylvania), LLM (Munich Intellectual Property Law Center) and Dr. iur. (the University of Augsburg) degrees.

Product Specifications

Brand: Springer
Format: Hardcover
ASIN: 3030867773
Category: Books > Subjects > Business, Finance & Law > Law > International
Domain: Amazon UK
Release Date: 20 October 2021
Listed Since: 07 August 2021

Barcode

No barcode data available

Springer Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law: 16 (Munich Studies on Innovation and Competition, 16)

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Springer - Mechanisms to Enable Follow-On Innovation (Vol 15)

A Copyright Gambit: On the Need for Exclusive Rights in Digitised Versions of Public Domain Textual Materials in Europe: 11 (Munich Studies on Innovation and Competition, 11)

EU Competition Law, Data Protection and Online Platforms: Data as Essential Facility: Data as Essential Facility (International Competition Law Series)

Regulatory Model for Digital Rights Management: Analysis of U.S., Europe and China

Smart Urban Mobility: Law, Regulation, and Policy: 29 (MPI Studies on Intellectual Property and Competition Law, 29)

Competition, Data and Privacy in the Digital Economy: Towards a Privacy Dimension in Competition Policy? (International Competition Law, 86)

The Unaccountable State of Surveillance: Exercising Access Rights in Europe: 34 (Law, Governance and Technology Series, 34)

Promoting Competition in Innovation Through Merger Control in the ICT Sector: A Comparative and Interdisciplinary Study: 10 (Munich Studies on Innovation and Competition, 10)

Personalized Medicine in Healthcare Systems: Legal, Medical and Economic Implications: 5 (Europeanization and Globalization, 5)

Personalized Medicine in Healthcare Systems: Legal, Medical and Economic Implications: 5 (Europeanization and Globalization, 5)

Acceptable Risk in Biomedical Research: European Perspectives: 50 (International Library of Ethics, Law, and the New Medicine, 50)

Competition Law in China: A Law and Economics Perspective

Contemporary Issues in Pharmaceutical Patent Law: Setting the Framework and Exploring Policy Options (Routledge Research in Intellectual Property)

Cross-Border Data Transfers Regulations in the Context of International Trade Law: A PRC Perspective

Pharmaceutical Innovation, Competition and Patent Law: A Trilateral Perspective

Trade Secrets Legal Protection: From a Comparative Analysis of US and EU Law to a New Model of Understanding: 19 (Munich Studies on Innovation and Competition, 19)

New Pathways to Civil Justice in Europe: Challenges of Access to Justice

Economic Impacts of Intellectual Property-Conditioned Government Incentives

Copyright Law in the Digital World: Challenges and Opportunities

The Laws of Transparency in Action: A European Perspective (Governance and Public Management)

The Laws of Transparency in Action: A European Perspective (Governance and Public Management)

Competition and Patent Law in the Pharmaceutical Sector: An International Perspective (International Competition Law, 65)

Regulating the Collaborative Economy in the European Union Digital Single Market

Springer Herausforderung Innovation: Eine interdisziplinare Debatte